

## Product datasheet for **TA590003**

### **p16INK4A (CDKN2A) Rabbit Polyclonal Antibody**

#### **Product data:**

<b>Product Type:</b>	Primary Antibodies
<b>Applications:</b>	ELISA
<b>Recommended Dilution:</b>	ELISA 1:200-2000
<b>Reactivity:</b>	Human
<b>Host:</b>	Rabbit
<b>Isotype:</b>	IgG
<b>Clonality:</b>	Polyclonal
<b>Immunogen:</b>	DNA immunization. This antibody is specific for the C Terminus Region of the target protein.
<b>Formulation:</b>	20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
<b>Concentration:</b>	1 mg/ml
<b>Purification:</b>	Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
<b>Conjugation:</b>	Unconjugated
<b>Storage:</b>	Store at -20°C as received.
<b>Stability:</b>	Stable for 12 months from date of receipt.
<b>Gene Name:</b>	cyclin dependent kinase inhibitor 2A
<b>Database Link:</b>	<a href="#">NP_000068</a> <a href="#">Entrez Gene 1029 Human</a> <a href="#">Q8N726</a>
<b>Background:</b>	p16 (cyclin-dependent kinase inhibitor 2A, INK4a) is a tumor suppressor protein. It is a specific inhibitor of Cdk 4 / Cdk 6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16 INK4a gene revealed homozygous deletions, nonsense, missense, or frame shift mutations in several human cancers. Although the frequency of p16 INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16 INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia



[View online »](#)

<b>Synonyms:</b>	ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4
<b>Note:</b>	This antibody was generated by SDIX's Genomic Antibody Technology® (GAT). <a href="#">Learn about GAT</a>
<b>Protein Families:</b>	Druggable Genome
<b>Protein Pathways:</b>	Bladder cancer, Cell cycle, Chronic myeloid leukemia, Glioma, Melanoma, Non-small cell lung cancer, p53 signaling pathway, Pancreatic cancer, Pathways in cancer